サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1660929

関節リウマチの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Rheumatoid Arthritis Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 211 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
関節リウマチの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年02月20日
発行: Persistence Market Research
ページ情報: 英文 211 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の関節リウマチの市場規模は、2025年に7億9,990万米ドルになるとみられ、2025年～2032年の予測期間に5.5%のCAGRで拡大し、2032年には11億6,360万米ドルに達すると予測されています。

関節リウマチは、主に関節を侵し、炎症、疼痛、進行性の関節損傷を引き起こす慢性自己免疫疾患です。関節リウマチ治療薬市場には、生物学的製剤、疾患修飾性抗リウマチ薬（DMARD）、非ステロイド性抗炎症薬（NSAID）、副腎皮質ステロイド薬など幅広い薬剤が含まれます。主な治療環境としては、病院、専門クリニック、在宅医療などがあり、患者は薬物療法と非薬物療法の両方を受けています。市場成長の原動力は、有病率の増加、認知度の向上、生物学的療法の進歩、ヘルスケアアクセスの改善です。

世界の関節リウマチ市場は、自己免疫疾患の罹患率の上昇、人口の高齢化、早期診断と治療オプションに関する患者の意識の高まりなど、複数の要因によって推進されています。関節リウマチの症状を管理し、疾患の進行を遅らせる効果を高める生物学的製剤や標的合成DMARDの採用が増加していることも、市場拡大に大きく寄与しています。さらに、長時間作用型注射剤や皮下投与製剤などのドラッグデリバリーシステムの技術的進歩により、患者のコンプライアンスと治療成績が向上しています。個別化医療の役割の拡大と、RA治療へのアクセスを改善するための政府の取り組みが、市場の成長をさらに後押ししています。

関節リウマチ市場は、バイオシミラーの進歩、新規標的治療薬の研究の増加、患者モニタリングのためのデジタルヘルスソリューションの統合などにより、大きな成長機会をもたらしています。AIを活用した創薬、併用療法、幹細胞治療を含む再生医療アプローチなどの新たな動向は、関節リウマチ治療におけるブレークスルーの可能性を提供します。製薬会社と研究機関の戦略的提携がイノベーションを促進し、遠隔医療やデジタル治療へのアクセス拡大が疾病管理を改善しています。さらに、ライフスタイルの改善、ホリスティックな治療アプローチ、患者中心のケアモデルへの注目の高まりは、市場参入企業が製品の提供を強化し、より幅広い患者層にアプローチするための新たな道を開いています。

当レポートでは、世界の関節リウマチ市場について調査し、検査タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 主要な市場動向

第4章 重要成功要因

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

第7章 世界市場の需要（価値または規模、100万米ドル）分析、2019年～2032年

  • 過去の市場規模（100万米ドル）分析、2019年～2024年
  • 現在および将来の市場規模（100万米ドル）分析と予測、2025年～2032年

第8章 世界市場分析、2019年～2032年、検査タイプ別

  • 過去の市場規模（100万米ドル）分析、検査タイプ別、2019年～2024年
  • 現在および将来の市場規模（100万米ドル）分析と予測、検査タイプ別、2025年～2032年
  • 検査タイプ別市場の魅力分析

第9章 世界市場分析、2019年～2032年、エンドユーザー別

  • 過去の市場規模（100万米ドル）分析、エンドユーザー別、2019年～2024年
  • 現在および将来の市場規模（100万米ドル）分析と予測、エンドユーザー別、2025年～2032年
  • エンドユーザー別市場の魅力分析

第10章 世界市場分析、2019年～2032年、地域別

  • 過去の市場規模（100万米ドル）分析、地域別、2019年～2024年
  • 現在および将来の市場規模（100万米ドル）分析と予測、地域別、2025年～2032年
  • 地域別市場の魅力分析

第11章 北米市場分析、2019年～2032年

第12章 ラテンアメリカ市場分析、2019年～2032年

第13章 欧州市場分析、2019年～2032年

第14章 東アジア市場分析、2019年～2032年

第15章 南アジア市場分析、2019年～2032年

第16章 オセアニア市場分析、2019年～2032年

第17章 中東・アフリカ市場分析、2019年～2032年

第18章 市場構造分析

第19章 競合分析

  • 競合ダッシュボード
  • ブランディングとプロモーション戦略
  • 主要開発分析
  • 競合の詳細
    • Abbott Diagnostics
    • Antibodies Incorporated
    • Beckman Coulter, Inc.
    • Euro Diagnostica AB
    • Thermo Fisher Scientific Inc.
    • Qiagen N.V.
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthcare GmbH
    • Janel Group (Antibodies Inc.)

第20章 使用される仮定と頭字語

第21章 調査手法

目次
Product Code: PMRREP4788

Persistence Market Research has recently released a comprehensive report on the worldwide market for rheumatoid arthritis (RA). The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global rheumatoid arthritis market from 2025 to 2032.

Key Insights:

  • Rheumatoid Arthritis Market Size (2025E): USD 799.9 Million
  • Projected Market Value (2032F): USD 1,163.6 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.5%

Rheumatoid Arthritis Market - Report Scope:

Rheumatoid arthritis is a chronic autoimmune disease that primarily affects joints, leading to inflammation, pain, and progressive joint damage. The market for RA treatment includes a wide range of drugs such as biologics, disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. Key treatment settings include hospitals, specialty clinics, and homecare settings, where patients receive both pharmacological and non-pharmacological therapies. Market growth is driven by increasing prevalence, rising awareness, advancements in biologic therapies, and improved healthcare access.

Market Growth Drivers:

The global rheumatoid arthritis market is propelled by multiple factors, including the rising incidence of autoimmune disorders, aging populations, and growing patient awareness regarding early diagnosis and treatment options. The increasing adoption of biologic and targeted synthetic DMARDs, which offer enhanced efficacy in managing RA symptoms and slowing disease progression, significantly contributes to market expansion. Additionally, technological advancements in drug delivery systems, such as long-acting injectables and subcutaneous formulations, are improving patient compliance and treatment outcomes. The expanding role of personalized medicine, along with government initiatives to improve access to RA treatments, further supports market growth.

Market Restraints:

Despite promising growth prospects, the rheumatoid arthritis market faces challenges, including the high cost of biologic drugs, limited healthcare access in low-income regions, and the risk of adverse effects associated with long-term RA treatments. Patent expirations of leading biologics are leading to increased competition from biosimilars, which, while enhancing affordability, may also impact the revenues of key market players. Additionally, stringent regulatory requirements and reimbursement constraints can pose barriers to market expansion, particularly in emerging economies with limited healthcare infrastructure.

Market Opportunities:

The rheumatoid arthritis market presents significant growth opportunities driven by advancements in biosimilars, increasing research into novel targeted therapies, and the integration of digital health solutions for patient monitoring. Emerging trends such as AI-driven drug discovery, combination therapies, and regenerative medicine approaches, including stem cell therapies, offer potential breakthroughs in RA treatment. Strategic collaborations between pharmaceutical companies and research institutions are fostering innovation, while expanding access to telemedicine and digital therapeutics is improving disease management. Furthermore, the growing focus on lifestyle modifications, holistic treatment approaches, and patient-centric care models is opening new avenues for market players to enhance their product offerings and reach a broader patient population.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the rheumatoid arthritis market globally?
  • Which drug classes and treatment approaches are shaping the future of RA management?
  • How are biosimilars influencing the competitive landscape of the rheumatoid arthritis market?
  • Who are the key players contributing to market growth, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global rheumatoid arthritis market?

Competitive Intelligence and Business Strategy:

Leading players in the global rheumatoid arthritis market, including AbbVie Inc., Pfizer Inc., Amgen Inc., and Johnson & Johnson, are focusing on innovation, strategic collaborations, and product differentiation to maintain a competitive edge. These companies are investing in R&D for next-generation biologics, biosimilars, and targeted therapies to improve treatment outcomes. Collaborations with healthcare providers and regulatory agencies are facilitating market access and promoting technology adoption. Additionally, increasing investments in digital health platforms, patient education, and clinical trials for novel drug candidates are shaping the competitive landscape of the RA market.

Key Companies Profiled:

  • AbbVie Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Johnson & Johnson
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • Roche Holding AG
  • Novartis AG
  • UCB S.A.

Key Segments Covered in Rheumatoid Arthritis Industry Research

Test Type

  • Serology Tests
  • Monitoring rheumatoid arthritis Treatment Efficiency Tests

End User

  • Hospitals
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. Adoption Analysis
  • 4.2. Key Regulations
  • 4.3. Cost Analysis, By Test Type
  • 4.4. Reimbursement Scenario
  • 4.5. Supply Chain Analysis
  • 4.6. PESTLE Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Autoimmune Disease Diagnostics Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Growing Healthcare Expenditure
    • 5.2.2. Increasing Adoption of Rheumatoid Arthritis Diagnostic Tests
    • 5.2.3. Prevalence of Arthritis Diseases
    • 5.2.4. New Product Launches
    • 5.2.5. Adoption of Off-Label Arthritis Diagnostic Procedures
    • 5.2.6. Increasing Research Activities to Expand Diagnostic Methods
    • 5.2.7. Study of Limited Specificity and Sensitivity of Rheumatoid Arthritis Test Kits
    • 5.2.8. Growing Awareness about Chronic Diseases
    • 5.2.9. Government Funding and Initiatives
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Test Type
    • 6.1.2. By End User
    • 6.1.3. By Country
  • 6.2. 2022 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019 - 2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019 - 2024
  • 7.2. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019 - 2032, By Test Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Test Type, 2019 - 2024
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Test Type, 2025 - 2032
    • 8.3.1. Serology Test
      • 8.3.1.1. Erythrocyte Sedimentation Rate (ESR)
      • 8.3.1.2. Rheumatoid Factor (RF)
      • 8.3.1.3. Anti-cyclic Citrullinated Peptide (anti-CCP)
      • 8.3.1.4. Antinuclear Antibody (ANA)
      • 8.3.1.5. Uric Acid
      • 8.3.1.6. Other Test
    • 8.3.2. Monitoring RA Treatment Efficiency Tests
      • 8.3.2.1. Salicylate Level Count
      • 8.3.2.2. Muscle Enzyme Test
      • 8.3.2.3. Creatinine Test
  • 8.4. Market Attractiveness Analysis By Test Type

9. Global Market Analysis 2019 - 2032, By End User

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis by End User, 2019 - 2024
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by End User, 2025 - 2032
    • 9.3.1. Hospitals
    • 9.3.2. Diagnostic Laboratories
      • 9.3.2.1. Private Laboratories
      • 9.3.2.2. Public Laboratories
    • 9.3.3. Ambulatory Surgical Centers
  • 9.4. Market Attractiveness Analysis by End User

10. Global Market Analysis 2019 - 2032, By Region

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis, by Region, 2019 - 2024
  • 10.3. Current and Future Market Size (US$ Mn) Analysis Forecast by Region, 2025 - 2032
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. East Asia
    • 10.3.5. South Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East & Africa
  • 10.4. Market Attractiveness Analysis by Region

11. North America Market Analysis 2019 - 2032

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis Trend Analysis by Market Taxonomy, 2019 - 2024
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Test Type
    • 11.3.3. By End User
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Test Type
    • 11.4.3. By End User
  • 11.5. Market Trends
  • 11.6. Key Market Participants - Intensity Mapping
  • 11.7. Drivers and Restraints - Impact Analysis
  • 11.8. Country Level Analysis & Forecast
    • 11.8.1. U.S. Market
      • 11.8.1.1. Introduction
      • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.1.2.1. By Test Type
        • 11.8.1.2.2. By End User
    • 11.8.2. Canada Market
      • 11.8.2.1. Introduction
      • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.2.2.1. By Test Type
        • 11.8.2.2.2. By End User

12. Latin America Market Analysis 2019 - 2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2019 - 2024
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
    • 12.3.1. By Country
      • 12.3.1.1. Mexico
      • 12.3.1.2. Brazil
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Test Type
    • 12.3.3. By End User
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Test Type
    • 12.4.3. By End User
  • 12.5. Market Trends
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. Mexico Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Test Type
        • 12.8.1.2.2. By End User
    • 12.8.2. Brazil Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Test Type
        • 12.8.2.2.2. By End User
    • 12.8.3. Argentina Market Analysis
      • 12.8.3.1. Introduction
      • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.3.2.1. By Test Type
        • 12.8.3.2.2. By End User

13. Europe Market Analysis 2019 - 2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis Trend Analysis by Market Taxonomy, 2019 - 2024
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. Italy
      • 13.3.1.3. France
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. BENELUX
      • 13.3.1.7. Russia
      • 13.3.1.8. Rest of Europe
    • 13.3.2. By Test Type
    • 13.3.3. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Test Type
    • 13.4.3. By End User
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Germany Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Test Type
        • 13.8.1.2.2. By End User
    • 13.8.2. Italy Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Test Type
        • 13.8.2.2.2. By End User
    • 13.8.3. France Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Test Type
        • 13.8.3.2.2. By End User
    • 13.8.4. U.K. Market Analysis
      • 13.8.4.1. Introduction
      • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.4.2.1. By Test Type
        • 13.8.4.2.2. By End User
    • 13.8.5. Spain Market Analysis
      • 13.8.5.1. Introduction
      • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.5.2.1. By Test Type
        • 13.8.5.2.2. By End User
    • 13.8.6. BENELUX Market Analysis
      • 13.8.6.1. Introduction
      • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.6.2.1. By Test Type
        • 13.8.6.2.2. By End User
    • 13.8.7. Russia Market Analysis
      • 13.8.7.1. Introduction
      • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.7.2.1. By Test Type
        • 13.8.7.2.2. By End User

14. East Asia Market Analysis 2019 - 2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2019 - 2024
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
    • 14.3.2. By Test Type
    • 14.3.3. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Test Type
    • 14.4.3. By End User
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. China Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Test Type
        • 14.8.1.2.2. By End User
    • 14.8.2. Japan Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Test Type
        • 14.8.2.2.2. By End User
    • 14.8.3. South Korea Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Test Type
        • 14.8.3.2.2. By End User

15. South Asia Market Analysis 2019 - 2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2019 - 2024
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Malaysia
      • 15.3.1.4. Thailand
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Test Type
    • 15.3.3. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Test Type
    • 15.4.3. By End User
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Test Type
        • 15.8.1.2.2. By End User
    • 15.8.2. Indonesia Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Test Type
        • 15.8.2.2.2. By End User
    • 15.8.3. Malaysia Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Test Type
        • 15.8.3.2.2. By End User
    • 15.8.4. Thailand Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Test Type
        • 15.8.4.2.2. By End User

16. Oceania Market 2019 - 2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis Trend Analysis By Market Taxonomy, 2019 - 2024
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Test Type
    • 16.3.3. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Test Type
    • 16.4.3. By End User
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Australia Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Test Type
        • 16.8.1.2.2. By End User
    • 16.8.2. New Zealand Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Test Type
        • 16.8.2.2.2. By End User

17. Middle East and Africa (MEA) Market Analysis 2019 - 2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis Trend Analysis by Market Taxonomy, 2019 - 2024
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2025 - 2032
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkiye
      • 17.3.1.3. North Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Test Type
    • 17.3.3. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Test Type
    • 17.4.3. By End User
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. GCC Countries Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Test Type
        • 17.8.1.2.2. By End User
    • 17.8.2. Turkiye Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Test Type
        • 17.8.2.2.2. By End User
    • 17.8.3. South Africa Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Test Type
        • 17.8.3.2.2. By End User
    • 17.8.4. North Africa Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Test Type
        • 17.8.4.2.2. By End User

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Branding and Promotional Strategies
  • 19.3. Key Development Analysis
  • 19.4. Competition Deep Dive
    • 19.4.1. Abbott Diagnostics
      • 19.4.1.1. Overview
      • 19.4.1.2. Service Portfolio
      • 19.4.1.3. Sales Footprint
      • 19.4.1.4. Key Financials
      • 19.4.1.5. SWOT Analysis
      • 19.4.1.6. Strategy Overview
        • 19.4.1.6.1. Marketing Strategy
        • 19.4.1.6.2. Diagnostic Test Strategy
        • 19.4.1.6.3. Channel Strategy
    • 19.4.2. Antibodies Incorporated
      • 19.4.2.1. Overview
      • 19.4.2.2. Service Portfolio
      • 19.4.2.3. Sales Footprint
      • 19.4.2.4. Key Financials
      • 19.4.2.5. SWOT Analysis
      • 19.4.2.6. Strategy Overview
        • 19.4.2.6.1. Marketing Strategy
        • 19.4.2.6.2. Diagnostic Test Strategy
        • 19.4.2.6.3. Channel Strategy
    • 19.4.3. Beckman Coulter, Inc.
      • 19.4.3.1. Overview
      • 19.4.3.2. Service Portfolio
      • 19.4.3.3. Sales Footprint
      • 19.4.3.4. Key Financials
      • 19.4.3.5. SWOT Analysis
      • 19.4.3.6. Strategy Overview
        • 19.4.3.6.1. Marketing Strategy
        • 19.4.3.6.2. Diagnostic Test Strategy
        • 19.4.3.6.3. Channel Strategy
    • 19.4.4. Euro Diagnostica AB
      • 19.4.4.1. Overview
      • 19.4.4.2. Service Portfolio
      • 19.4.4.3. Sales Footprint
      • 19.4.4.4. Key Financials
      • 19.4.4.5. SWOT Analysis
      • 19.4.4.6. Strategy Overview
        • 19.4.4.6.1. Marketing Strategy
        • 19.4.4.6.2. Diagnostic Test Strategy
        • 19.4.4.6.3. Channel Strategy
    • 19.4.5. Thermo Fisher Scientific Inc.
      • 19.4.5.1. Overview
      • 19.4.5.2. Service Portfolio
      • 19.4.5.3. Sales Footprint
      • 19.4.5.4. Key Financials
      • 19.4.5.5. SWOT Analysis
      • 19.4.5.6. Strategy Overview
        • 19.4.5.6.1. Marketing Strategy
        • 19.4.5.6.2. Diagnostic Test Strategy
        • 19.4.5.6.3. Channel Strategy
    • 19.4.6. Qiagen N.V.
      • 19.4.6.1. Overview
      • 19.4.6.2. Service Portfolio
      • 19.4.6.3. Sales Footprint
      • 19.4.6.4. Key Financials
      • 19.4.6.5. SWOT Analysis
      • 19.4.6.6. Strategy Overview
        • 19.4.6.6.1. Marketing Strategy
        • 19.4.6.6.2. Diagnostic Test Strategy
        • 19.4.6.6.3. Channel Strategy
    • 19.4.7. F. Hoffmann-La Roche Ltd.
      • 19.4.7.1. Overview
      • 19.4.7.2. Service Portfolio
      • 19.4.7.3. Sales Footprint
      • 19.4.7.4. Key Financials
      • 19.4.7.5. SWOT Analysis
      • 19.4.7.6. Strategy Overview
        • 19.4.7.6.1. Marketing Strategy
        • 19.4.7.6.2. Diagnostic Test Strategy
        • 19.4.7.6.3. Channel Strategy
    • 19.4.8. Siemens Healthcare GmbH
      • 19.4.8.1. Overview
      • 19.4.8.2. Service Portfolio
      • 19.4.8.3. Sales Footprint
      • 19.4.8.4. Key Financials
      • 19.4.8.5. SWOT Analysis
      • 19.4.8.6. Strategy Overview
        • 19.4.8.6.1. Marketing Strategy
        • 19.4.8.6.2. Diagnostic Test Strategy
        • 19.4.8.6.3. Channel Strategy
    • 19.4.9. Janel Group (Antibodies Inc.)
      • 19.4.9.1. Overview
      • 19.4.9.2. Service Portfolio
      • 19.4.9.3. Sales Footprint
      • 19.4.9.4. Key Financials
      • 19.4.9.5. SWOT Analysis
      • 19.4.9.6. Strategy Overview
        • 19.4.9.6.1. Marketing Strategy
        • 19.4.9.6.2. Diagnostic Test Strategy
        • 19.4.9.6.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology